The U.S. Supreme Court rejects appeals from pharmaceutical companies that challenge the federal government’s ability to negotiate Medicare drug prices. The dispute centers on a Medicare negotiation program created under the 2022 Inflation Reduction Act. Supporters of the law argue that allowing the government to negotiate directly with drug manufacturers helps set prices more effectively, while opponents contend it exceeds the government’s authority or otherwise violates legal constraints.
Multiple outlets report that the Supreme Court declines to hear or overturn the companies’ challenges, leaving the negotiation framework in place. The program ends a long-running debate over whether the federal government can “haggle” directly with manufacturers over drug pricing in Medicare. As a result of the Court’s decision, the existing legal pathway for the negotiation program remains intact and drugmakers’ efforts to block the policy through the courts fail at the Supreme Court level.
The decision applies to the companies’ appeals regarding Medicare price negotiations, and the negotiations continue under the Inflation Reduction Act framework.
